Saquinavir: An HIV Proteinase Inhibitor

  • Keith Bragman
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 394)


The human immunodeficiency virus (HIV) proteinase has been recently identified as a potential target, distinct from reverse transcriptase, for antiretroviral therapy.1 Although reverse transcriptase inhibitors block viral replication in newly-infected cells by preventing this early step in the HIV replicative cycle, such antiretrovirals have no effect on virus production by cells in which reverse transciption and integration have already occurred, ie. in chronically infected cells. As a functional proteinase is essential for the release of infectious virions, this enzyme represents an extremely attractive target for rationale drug design and therapeutic intervention (Figure 1).2


Human Immunodeficiency Virus Type Nucleoside Analogue Triple Combination Human Immunodeficiency Virus Proteinase Inhibitor Zidovudine Monotherapy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Robins T, Plattner J. HIV Proteinase inhibitors: their anti-HIV activity and potential role in treatment. J Acquir Immune Defic Syndr 1993; 6: 162–170.PubMedGoogle Scholar
  2. 2.
    Roberts NA, Matin JA, Kinchington D, et al. Rational design of peptide based HIV proteinase inhibitors. Science. 1990; 248: 358–361.PubMedCrossRefGoogle Scholar
  3. 3.
    Navia MA, Fitzgerald PMD, McKever BM, et al. Three dimensional structure of aspartyl protease from human immunodeficiency virus HIV-1. Nature 1989; 337: 615–20.PubMedCrossRefGoogle Scholar
  4. 4.
    Criag JC, Duncan IB, HockelyD, Grief C, Roberts NA, Mills JS. Antiviral properties of Ro 31–8959, an inhibitor of human immunodeficiency virus (HIV) proteinase. Antiviral Res 1991; 16: 295–305.CrossRefGoogle Scholar
  5. 5.
    Johnson VA, Merrill P, Chou TC, Hirsch MS. Human immunodeficiency virus type l (HIV-1) inhibitory interactions between proteinase inhibitor Ro 31–8959 and zidovudine, 2’3’-dideoxycytidine, or recombinant interferon alfa against zidovudine-sensitive or resistant HIV-1 in vitro. J Infect Dis 1992; 166: 1143–6.PubMedCrossRefGoogle Scholar
  6. 6.
    Craig JC, Duncan IB, Whittaker L, Roberts NA. Antiviral synergy between inhibitors of HIV proteinase and reverse transcriptase. Antiviral Chemistry and Chemotherapy 1990; 4: 161–166.Google Scholar
  7. 7.
    Craig JC, Grief C, Mills JS, Hockley D, Duncan 1B, Roberts NA. Effects of a specific inhibitor of HIV proteinase (Ro 31–8959) on virus maturation in a chronically infected promonocytic cell line (U Antiviral Chem Chemother 1991; 2: 181–186.Google Scholar
  8. 8.
    Kramer RA, Schaber MD, Slalka AM, Ganguly K, Wong-Stall F, Reddy EP. HTLA III gag protein is processed in yeast cells by the virus pol proteinase. Science 1986; 231: 1580–1584.PubMedCrossRefGoogle Scholar
  9. 9.
    Johnson VA, Walker BD, Barlow MA, Paradis TJ, Chou TC, Hirsch MS. Synergistic inhibition of human immunodeficiency virus type 1 and 2 replication in vitro by castanospermine and 3’-azido-3’deoxythymidine. Antimicrob Agents Chemother 1989; 33: 53–57.PubMedCrossRefGoogle Scholar
  10. 10.
    Johnson VA, Barlow MA, Chou TC, Fischer RA, Walker BD, Hirsch MS, Schooley RT. Synergistic inhibition of human immunodeficiency virus type 1 (HIV-1) replication in vitro by recombinant soluble CD4 and 3’-azido-3’-azido-3’deoxythymidine. J Infect Dis 1989; 159: 837–844.PubMedCrossRefGoogle Scholar
  11. 10a.
    Mazzuli T, Hirsch MS. Combination Therapy for HIV Infection. In Mills J, Corey L (editors), Antiviral Chemotherapy, Vol 3. PTR Prentice Hall, 1993; 385–416.Google Scholar
  12. 11.
    Balzarini J, Herdewijn P, de Clercq E. Differential patterns of intracellular metabolism of 2’,3’-didehydro2’,3’-dideoxythymidine and 3’-azido-2’,3’-dideoxythimidine, two potent anti-human immunodeficiency virus compounds. J Biol Chem 1989; 264: 6127–6133.PubMedGoogle Scholar
  13. 12.
    Meng TC, Fischi MA, Boota AM, Spector S, Bennett D. Combination therapy with zidovudine and dideoxycytidine in patients with advanced human immunodeffrciency virus infection. A phase I/II study. Annals Int Med 1992; 116: 13–20.CrossRefGoogle Scholar
  14. 13.
    Richman DD, Kornbluth RS, Carson DA. Failure of dideoxynucleosides to inhibit human inununodeficiency virus replication in cultured human macrophages. J Exp Med 1987; 166: 1144–1149.PubMedCrossRefGoogle Scholar
  15. 14.
    Craig J, Whittaker L, Duncan I, Roberts N. In vitro anti-HIV and cytotoxicological evaluation of the triple combination: AZT and ddC with HIV proteinase inhibitor saquinavir (Ro 31–8959). Antiviral Chemistry and Chemotherapy. 1994; 5: 380–386.Google Scholar
  16. 15.
    D’Aquila R, Johnson V, Welles S et at. Zidovudine resistance and HIV-1 disease progression during antiretroviral therapy. Ann Int Med 122(6):401–407.Google Scholar
  17. 16.
    Richman DD. HIV drug resistance. AIDS Res Human Retrovirus 1992; 8: 1065–1071.CrossRefGoogle Scholar
  18. 17.
    Craig JC, Whittaker L, Duncan IB, Roberts NA. In vitro resistance to an inhibitor of HIV proteinase (Ro 31–8959) relative to inhibitors of reverse transcriptase (AZT and TIRO). Antiviral Chem Chemother. 1993; 4: 335–339.Google Scholar
  19. 18.
    Jacobsen H, Yasargil K, Winslow D, Craig J, Krohn A, Duncan I, Mous J. Characterization of human immunodeficiency virus TYPE I mutants with decreased sensitivity to protease inhibitor Ro 31–8959. Virology 1995; 206: 527–534.PubMedCrossRefGoogle Scholar
  20. 19.
    Otto MJ, Garber S, Winslow DL, Reid CD, Aldrich P, Jadhar PK, Patterson CE, Hodge CN, Cheng YSE. In vitro isolation and identification of human immunodeficiency virus (HIV) variants with reduced sensitivity to C-2 symmetrical inhibitors of HIV type 1 protease. Proc Natl Acad Sci USA 1993; 90: 75437547.Google Scholar
  21. 20.
    Kitchen VS, Skinner C, Ariyoshi K, Lane EA, Duncan IB, Burckhardt J, Burger HU, Bragman K, Pinching AJ, Weber JN. Safety and activity of saquinavir in HIV infection. The Lancet 1995; 345: 952–955.CrossRefGoogle Scholar
  22. 21.
    Delfraissy JF, Sereni D, Brun-Vezinet F, Dussaix E, Krivine A, Dormont Jet al. A phase I-II dose ranging study of the safety and activity of Ro 31–8959 (HIV-proteinase inhibitor) in previously Zidovudine (ZDV) treated HIV-infected individuals. IXth International Conference on AIDS, Berlin, June 1993, Abstract, WS-B26–3.Google Scholar
  23. 22.
    Vella S. (1995) submitted for publication.Google Scholar
  24. 23.
    Basset R, Schoenfeld D, Collier A. Double blind, randomized Phase II study of Ro 31–8959 + zidovudine vs zidovudine + zalcitabine vs Ro 31–8959 +zidovudine + zalcitabine, ACTG 229 Executive Summary, May 26, 1994.Google Scholar
  25. 24.
    Mulder J, McKinney N, Christopherson C, Sninsky J, Greenfield L, Kwok S. Rapid and simple PCR assay for quantitation of human immunodeficiency virus type 1 RNA in plasma: Application to acute retroviral infection. J Clin Microbiol. 1994; 32: 292–300.PubMedGoogle Scholar
  26. 25.
    Jacobsen H. (unpublished observations, 1995).Google Scholar

Copyright information

© Springer Science+Business Media New York 1996

Authors and Affiliations

  • Keith Bragman

There are no affiliations available

Personalised recommendations